Stryker Corporation $SYK Stock Holdings Lessened by Choreo LLC

Choreo LLC lessened its holdings in shares of Stryker Corporation (NYSE:SYK) by 9.0% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 14,943 shares of the medical technology company’s stock after selling 1,471 shares during the period. Choreo LLC’s holdings in Stryker were worth $5,924,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the business. Rhenman & Partners Asset Management AB bought a new position in shares of Stryker during the second quarter valued at approximately $4,550,000. Maia Wealth LLC bought a new position in Stryker during the 2nd quarter worth $531,000. FourThought Financial Partners LLC grew its stake in Stryker by 15.3% during the 2nd quarter. FourThought Financial Partners LLC now owns 1,274 shares of the medical technology company’s stock worth $504,000 after buying an additional 169 shares during the last quarter. Associated Banc Corp increased its position in Stryker by 3.7% in the second quarter. Associated Banc Corp now owns 23,088 shares of the medical technology company’s stock worth $9,134,000 after buying an additional 826 shares during the period. Finally, Columbia Bank lifted its stake in Stryker by 3.0% in the second quarter. Columbia Bank now owns 5,987 shares of the medical technology company’s stock valued at $2,332,000 after buying an additional 177 shares during the last quarter. Institutional investors own 77.09% of the company’s stock.

Stryker Price Performance

Shares of NYSE:SYK opened at $372.04 on Thursday. The stock has a market cap of $142.28 billion, a price-to-earnings ratio of 49.28, a PEG ratio of 2.66 and a beta of 0.94. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.78 and a quick ratio of 1.06. Stryker Corporation has a 12 month low of $329.16 and a 12 month high of $406.19. The stock’s 50 day moving average price is $369.13 and its 200 day moving average price is $380.49.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Thursday, October 30th. The medical technology company reported $3.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.13 by $0.06. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The company had revenue of $6.06 billion for the quarter, compared to analysts’ expectations of $6.04 billion. During the same period last year, the firm earned $2.87 EPS. The firm’s revenue for the quarter was up 10.2% on a year-over-year basis. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. Equities research analysts anticipate that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently weighed in on SYK. Truist Financial increased their price objective on shares of Stryker from $392.00 to $400.00 and gave the stock a “hold” rating in a report on Friday, November 14th. BTIG Research restated a “buy” rating and issued a $410.00 target price on shares of Stryker in a research report on Friday, November 14th. Rothschild Redb raised Stryker to a “hold” rating in a report on Thursday, September 18th. Needham & Company LLC reiterated a “buy” rating and set a $448.00 price objective on shares of Stryker in a research report on Friday, November 14th. Finally, Weiss Ratings restated a “hold (c+)” rating on shares of Stryker in a research report on Tuesday. Thirteen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $434.37.

Insider Buying and Selling

In other Stryker news, CFO Preston Wendell Wells sold 165 shares of the business’s stock in a transaction dated Thursday, November 20th. The shares were sold at an average price of $365.88, for a total value of $60,370.20. Following the sale, the chief financial officer directly owned 6,694 shares in the company, valued at approximately $2,449,200.72. The trade was a 2.41% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Ronda E. Stryker sold 276,173 shares of the company’s stock in a transaction dated Thursday, November 6th. The shares were sold at an average price of $353.28, for a total transaction of $97,566,397.44. Following the completion of the sale, the director directly owned 2,702,108 shares of the company’s stock, valued at $954,600,714.24. The trade was a 9.27% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 522,118 shares of company stock valued at $185,381,932 over the last three months. Company insiders own 5.90% of the company’s stock.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.